The term “cannabinoid” refers to one of a number of chemical compounds found in the weed plant. Cannabidiol (CBD), is the non psychoactive component of cannabinoids. Tetrahydrocannabinol (THC) is another component of the cannabis plant which is in fact psychoactive. Products made with CBD are becoming ever so popular now because they have the ability to reduce inflammation in animal cells. Multiple sclerosis (MS) affects the immune system and is associated with muscle stiffness, spasms, pain, and tremor. Much anecdotal evidence suggests that cannabinoids could help these symptoms. People have used medical marijuana for MS treatment in the past and now people are using CBD cannabis based oils to treat progressive MS. The aim of this paper is to see if cannabinoids have a beneficial effect on spasticity and other symptoms related to multiple sclerosis.
Here is the full scientific article if you wish to download it.
In this study, CBD and THC were given to a number of patients for treatment of MS and muscle spasticity. The Ashworth scale measured the overall spasticity in the patients. The results showed that treatment was effective on most of the patients who were treated with CBD and THC. This means that pain was relieved which suggest that cannabinoids may be clinically useful.
Treatment with cannabinoids did not improve spasticity associated with multiple sclerosis as measured with the Ashworth scale, but did conclude in some benefits including improvement in mobility and the patients’ perceptions of the effect of spasticity. In the past, other studies have shown that cannabinoids can infact improve disease-related spasticity, however more research will need to take place as results in each study are conflicting.
This paper provides good evidence for the effects of medical cannabis as an indicator in how it can treat the side effects of multiple sclerosis, however results say that it will not improve spasticity from this disease.